Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events

Overview

About this study

The purpose of this study is to use patient blood cells to perform individualized in vitro modeling of cancer therapy-related toxicities.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Any patient >18 years of age.
  • Planned or receiving any potentially toxic cancer therapy including but not limited to chemotherapy, targeted and immunotherapies.

Exclusion Criteria: 

  • Inability on the part of the patient to understand the informed consent or be compliant with the protocol.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/15/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Nadine Norton, Ph.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions